This cardioprotective effect in cancer patients has been observed regardless of the presence of diabetes, underscoring the broader therapeutic potential of SGLT2 inhibitors as an adjunct treatment for managing cardiac complications in oncological care [4,5]. This evidence concerns the gene SLC5A2 and diabetes mellitus.